kanamycin, or amikacin) (4); no remarkable change in duration of treatment resulted when those 4 cases were removed from analysis.

The surveillance system captures only the initial treatment regimen; thus, we could not assess changes to treatment regimens in response to drug susceptibility test results or treatment nonadherence. We observed no difference in history of prior TB; HIV infection; or military, meningeal, pediatric, or bone and joint TB among case-patients with isoniazid-resistant versus drug-susceptible TB (p>0.12 for all comparisons). TB treatment recommendations in the United States emphasize completion within 12 months of initiating therapy, with exceptions for rifampin-resistant TB, meningeal TB, and disseminated disease in pediatric patients (children <15 years of age) (1,5). We found no change in treatment duration by drug-resistance pattern after removing cases of meningeval TB or cases in children from analysis.

The length of TB treatment duration in the United States has improved since therapy outcomes were first recorded in the National TB Surveillance System in 1993. In our study, 90% of case-patients with drug-susceptible TB completed therapy within 373 days, compared with 671 days in 1993 (6), and 90% of patients with isoniazid-monoresistant TB completed therapy within 432 days. Although the percentage of MDR TB cases in the United States has declined since 1993, drug resistance remains a serious concern because the percentage of isoniazid-monoresistant TB cases has remained stable (7). Our analysis suggests that despite the effectiveness of rifampin-containing regimens and an apparent lack of clinical differences to justify extending therapy, longer treatment durations persist among patients with isoniazid-monoresistant TB (8). In our cohort study, <75% of patients with rifampin-monoresistant TB and 40% with MDR TB completed therapy within 24 months, suggesting no improvement since 1993 in the length of treatment duration for rifampin-resistant TB strains (6).

Acknowledgments

We acknowledge the state and local health department personnel who treat TB patients and collect and report the data used for these analyses. We thank Thomas Navin for comments on earlier versions of this letter.

Carla A. Winston and Kiren Mitruka
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

DOI: http://dx.doi.org/10.3201/eid1807.120261

References

1. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2008. Atlanta (GA): US Department of Health and Human Services; 2009.
2. LoBue PA, Enarson DA, Thoen TC. Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States. Int J Tuberc Lung Dis. 2010;14:1226–32.
3. Blumberg HM, Burman WJ, Chaissou RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62. http://dx.doi.org/10.1164/rccm.167.4.603
4. Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 2006;55:1176.
5. Mitruka K, Winston CA, Navin TR. Predictors of failure in timely tuberculosis treatment completion, United States. Int J Tuberc Lung Dis. 2012;16. In press.
6. Bloch AB, Cauthen GM, Simone PM, Kelly GD, Damsbury KG, Castro KG. Completion of tuberculosis therapy for patients reported in the United States in 1993. Int J Tuberc Lung Dis. 1999;3:273–80.
7. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med. 2008;168:1984–92. http://dx.doi.org/10.1001/archinte.168.19.1984
8. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical Characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis. 2009;48:179–85. http://dx.doi.org/10.1086/595689

Address for correspondence: Carla A. Winston, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E91, Atlanta, GA 30333, USA; email: cwinston@cdc.gov

Exposure of US Travelers to Rabid Zebra, Kenya, 2011

To the Editor: Rabies is an acute progressive encephalitis caused by infection with a lyssavirus (genus Lyssavirus, family Rhabdoviridae) (1). Most human infections are caused by bites from rabid animals, but the virus also can be transmitted by contact of open wounds or mucous membranes with animal saliva (1,2). Prompt administration of postexposure prophylaxis (PEP) is recommended to prevent rabies (3). Canids are common sources of human exposures in many regions of Africa, Asia, and Latin America (4). However, all mammals are susceptible, including herbivores such as horses, cattle, and antelope (5–7).

Approximately 16–200 rabies virus exposures occur per 100,000 international travelers (2). Travelers might be unaware of exposure risks from less commonly affected species because prevention guidelines focus on avoiding contact with feral and wild carnivores (primarily dogs) and bats (2). After travelers at a safari lodge in Kenya were exposed to a rabid zebra, the Centers for Disease Control and Prevention (CDC) and international partners conducted
a contact investigation to ensure affected travelers received timely exposure assessments and appropriate PEP recommendations.

In January 2011, an orphaned zebra foal was taken to a safari lodge for care. Tourists were permitted to view, pet, and feed the zebra. A dog suspected of being rabid bit the zebra on July 31. Attempts to capture the dog for testing were unsuccessful. The zebra became ill around August 24 and died on August 26 (Figure).

Rabies was suspected because of neurologic signs and was diagnosed in the zebra after detection of rabies virus antigens by direct fluorescent antibody testing at the Kenya Central Veterinary Laboratory. Lodge staff received results on August 30 and immediately communicated the information to travelers who had visited during July 24–August 26 by email through booking travel agents (because lodge staff did not have traveler contact information). This email conveyed the diagnosis and information about rabies virus transmission and vaccine and advised travelers to consult their physicians if they believed they were at risk.

On September 1, after receiving the email, several US travelers reported contact with the zebra’s mouth and saliva to state health officials. State health officials notified CDC that same day. CDC initiated a contact investigation of US travelers; the World Health Organization International Health Regulations Office coordinated contact investigation for non-US travelers. The Kenya Ministry of Public Health and Sanitation, Field Epidemiology and Laboratory Training Program, and the Kenya Wildlife Service performed environmental assessments, evaluated lodge staff and animal exposures, and reviewed bite surveillance and preparedness in the surrounding district. CDC Rabies Program staff corroborated the rabies diagnosis and genotyped the variant as one associated with dogs in Africa, supporting the presumed transmission through dog bite.

On September 8, lodge staff provided CDC with travelers’ surnames, number of travelers per group, countries of citizenship and residence, and travel agent contact information. Of 243 travelers, 136 (56%) were US residents from 14 states (online Technical Appendix Table 1, wwwnc.cdc.gov/EID/pdfs/12-0081-Techapp.pdf). The remaining 107 travelers were residents of 16 countries, primarily in Europe (online Technical Appendix Figure). CDC obtained traveler contact information from travel agents. State health officials contacted US travelers by telephone or email.

Viral shedding duration for rabid zebras is unknown. An infectious period was estimated as the 14 days from the foal’s illness until its death (August 10–26) (8). Of 136 US travelers, 77 (57%) visited the lodge during this period. The remaining 59 US travelers who visited during July 24–August 9 also were contacted to document medical assistance received and to provide rabies education.

Twenty-eight (21%) US travelers had already initiated PEP when interviewed by state public health officials. Exposure risk categories based on Advisory Committee on Immunization Practices recommendations were developed to address the unique circumstances of this investigation, i.e., the period and nature of travelers’ exposures to the zebra (online Technical Appendix Table 2) (3). None reported high-risk exposures; 2 reported moderate-risk exposures; and 26 reported low- or no-risk exposures, for which PEP would not have been recommended. CDC has not received any reports of human rabies in travelers exposed to the zebra in this incident.

Initial exposure notifications to travelers were delivered by travel agents, rather than public health officials. Public health intervention was delayed while travel contact information was obtained. During this delay, travelers sought care from private physicians who made time-sensitive PEP decisions with incomplete information, resulting in unnecessary PEP administration according to published standards (3). Unnecessary PEP should be avoided because rabies biologicals are expensive (averaging $4,000/patient [9]), and rabies PEP entails small but real risk for adverse events (3). Inclusion of a health provision in travel agency privacy agreements to permit release of traveler contact information for public health use would improve response times for similar events.

Figure. Timeline of events for traveler exposures to a rabid zebra and subsequent contact investigation of US travelers, Kenya, January 2011–September 2011. CDC, Centers for Disease Control and Prevention; WHO-IHR, World Health Organization’s International Health Regulations Office.
Travelers to rabies-endemic regions should avoid contact with wild and feral animals, even in seemingly safe captive settings (2). Any mammal can be rabid, and infectious animals might appear healthy for several days before illness onset; avoiding all wild and feral animals while traveling is the ideal preventive measure. All animal bites and scratches should be washed thoroughly with soap and water and receive immediate medical attention (2).

Acknowledgments

We thank affected travelers for participating in this investigation and their assistance in reaching travelers. We are also grateful to the Kenya Central Veterinary Laboratory and to Michael Niezgoda, Ivan Kuzmin, and the staff of the CDC Rabies Program for laboratory support. Finally, we thank all collaborators at the Department for Disease Surveillance and Response and Field Epidemiology and Laboratory Training Program at the Kenya Ministry of Public Health and Sanitation, Kenya Wildlife Service, Kenya Ministry of Forestry, Kenya Ministry of Livestock Development, the World Health Organization’s International Health Regulations Office, and all US state public health partners for their support and partnership during this investigation.

Emily W. Lankau, Joel M. Montgomery, Danielle M. Tack, Mark Obonyo, Samuel Kadivane, Jesse D. Blanton, Wences Arvelo, Emily S. Jentes, Nicole J. Cohen, Gary W. Brunette, Nina Marano, and Charles E. Rupprecht

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.W. Lankau, D.M. Tack, J.D. Blanton, E.S. Jentes, N.J. Cohen, G.W. Brunette, N. Marano, C.E. Rupprecht); Centers for Disease Control and Prevention, Nairobi, Kenya (J.M. Montgomery, W. Arvelo); and Ministry of Public Health and Sanitation, Nairobi (M. Obonyo, S. Kadivane)

DOI: http://dx.doi.org/10.3201/eid1807.120081

References

1.  Rupprecht CE, Hanlon CA, Hemachudha T. Rabies reexamined. Lancet Infect Dis. 2002;2:327–43. http://dx.doi.org/10.1016/S1473-3099(02)00287-6
2.  Brunette GW, editor: CDC health information for international travel, 2012 (the yellow book). New York: Oxford University Press; 2011.
3.  Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumertdacha B, Guerra M, et al.; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008;57(RR-3):1–28.
4.  Cleaveland S, Kaare M, Knobel D, Laurenson MK. Canine vaccination—providing broader benefits for disease control. Vet Microbiol. 2006;117:43–50. http://dx.doi.org/10.1016/j.vetmic.2006.04.009
5.  Berry HH. Surveillance and control of anthrax and rabies in wild herbivores and carnivores in Namibia. Rev Sci Tech. 1993;12:137–46.
6.  Pan American Health Organization. Rabies (ICD-10 A82). Zoonosis and communicable diseases common to man and animals, 3rd ed. Washington (DC): The Organization; 2003. p. 246–75.
7.  Pfaukenyi DM, Pawandiwa D, Makaya PV, Ushewokunze-Obatolu U. A retrospective study of wildlife rabies in Zimbabwe, between 1992 and 2003. Trop Anim Health Prod. 2009;41:565–72. http://dx.doi.org/10.1007/s11250-008-9224-4
8.  Feder HM, Nelson RS, Cartter ML, Sade I. Rabies prophylaxis following the feeding of a rabid pony. Clin Pediatr (Phila). 1998;37:477–81. http://dx.doi.org/10.1177/000992289803700803
9.  Shwiff SA, Sterner RT, Jay MT, Parikh S, Bellomy A, Meltzer MI, et al. Direct and indirect costs of rabies exposure: a retrospective study in southern California (1998–2002). J Wildl Dis. 2007;43:251–7.

Address for correspondence: Emily W. Lankau, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop C01, Atlanta, GA 30333, USA; email: vij3@cdc.gov

LETTERS

Culicoids as Vectors of Schmallenberg Virus

To the Editor: In autumn 2011, an unidentified disease of livestock was reported on both sides of the Dutch–Germany border. By using metagenomics, the etiologic agent of this disease was identified as a novel orthobunyavirus and named Schmallenberg virus (SBV) (1). Other members of the genus Orthobunyavirus (e.g., Akabane virus) are widespread in Africa and Asia; biting midges (Culicoides spp.) and mosquitoes are responsible for transmitting these viruses. Hence, we reasonably assumed that European culicoids might be responsible for transmitting SBV within Europe. We present evidence that culicoids captured October 2011 in Denmark contained SBV RNA and most likely are vectors for this agent.

In autumn 2011, culicoids were collected from several sites within Denmark. One site, a chicken farm in Høkkerup (online Appendix Figure, wwwnc.cdc.gov/EID/article/18/7/12-0385-F1.htm), was selected for study because of its location close (6 km) to the German border and proximity (<10 km) to an SBV-infected sheep farm in Germany, as reported on March 9, 2012, by the Friedrich Loeffler Institute surveillance website (www.fli.bund.de). The culicoids were collected during October 14–16 by using a Mosquito Magnet Independence trap (Mosquito Magnet, Lititz, PA, USA) baited with carbon dioxide and octenol. Midges were sorted manually into 91 specimens of the C. obsoletus group (comprising C. obsoletus, C. chiopterus, C. dewulfi, and C. scoticus) and 17 of the C. punctatus sensu stricto group, then stored at −20°C.

Pools of culicoids were homogenized in water (100 μL) by
Exposure of US Travelers to Rabid Zebra, Kenya, 2011

Technical Appendix

| State of residence | Travel period Jul 24–Aug 9 | Travel period Aug 10–26 Contact* | No contact | Total |
|--------------------|-----------------------------|----------------------------------|------------|-------|
| California         | 3                           | 12                               | 13         | 28    |
| Texas              | 11                          | 2                                | 2          | 15    |
| New York           | 1                           | 3                                | 9          | 13    |
| Maryland           | 9                           | 3                                | 0          | 12    |
| Washington         | 0                           | 5                                | 6          | 11    |
| New Jersey         | 6                           | 4                                | 0          | 10    |
| Virginia           | 0                           | 3                                | 5          | 8     |
| Florida            | 2                           | 0                                | 5          | 7     |
| Pennsylvania       | 7                           | 0                                | 0          | 7     |
| Colorado           | 4                           | 1                                | 0          | 5     |
| Connecticut        | 5                           | 0                                | 0          | 5     |
| Illinois           | 5                           | 0                                | 0          | 5     |
| Indiana            | 2                           | 0                                | 0          | 2     |
| Utah               | 2                           | 0                                | 0          | 2     |
| Unknown            | 2                           | 0                                | 4          | 6     |
| Total              | 59                          | 33                               | 44         | 136   |

*Direct physical contact with the zebra as self-reported by travelers.

| Exposure category | Period of contact | Description | Description |
|-------------------|-------------------|-------------|-------------|
| High risk         | Aug 10–26*        | Traveler reported being bitten† by the zebra or having fresh, wet zebra saliva in direct contact with open skin wounds or mucous membranes. |
| Moderate risk     | Aug 10–26*        | Traveler reported having skin contact with fresh, wet zebra saliva and reported the possibility of skin wounds at contact. |
| Low risk          | Aug 10–26*        | Traveler reported having touched or fed the zebra but no contact between fresh, wet saliva and open wounds or mucous membranes. |
| No risk           | Jul 24–Aug 9      | Contact with the zebra occurred before the infectious period. |

*Estimated infectious period.
†None of the US travelers contacted reported being bitten by the zebra.
Technical Appendix Figure. Contact investigation outcomes for 136 US travelers, by travel period and postexposure prophylaxis (PEP) outcomes, Kenya, July 24–August 26, 2011. Exposure risk categories are defined in Technical Appendix Table 2.